Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell-Depleting Agents

We measured cytomegalovirus (CMV)-specific antibodies that neutralize epithelial cell infection (CMV-AbNEIs) in 101 CMV-seropositive kidney transplant recipients (KTRs) at baseline and posttransplant months 3 and 6. All the patients received antithymocyte globulin and 3-month valganciclovir prophyla...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2024-06, Vol.229 (6), p.1812-1816
Main Authors: Fernández-Ruiz, Mario, García-Ríos, Estéfani, Redondo, Natalia, Rodríguez-Goncer, Isabel, Ruiz-Merlo, Tamara, Parra, Patricia, Sandonis, Virginia, López-Medrano, Francisco, San Juan, Rafael, González, Esther, Polanco, Natalia, Andrés, Amado, Navarro, David, Aguado, José María, Pérez-Romero, Pilar
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - blood
Antilymphocyte Serum - therapeutic use
Antiviral Agents - therapeutic use
Clinical Relevance
Cytomegalovirus - immunology
Cytomegalovirus Infections - immunology
Female
Humans
Kidney Transplantation - adverse effects
Lymphocyte Depletion
Male
Middle Aged
T-Lymphocytes - immunology
Transplant Recipients
Valganciclovir - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We measured cytomegalovirus (CMV)-specific antibodies that neutralize epithelial cell infection (CMV-AbNEIs) in 101 CMV-seropositive kidney transplant recipients (KTRs) at baseline and posttransplant months 3 and 6. All the patients received antithymocyte globulin and 3-month valganciclovir prophylaxis. There were no significant differences in pretransplant AbNEIs titers between KTRs that developed or did not develop any-level CMV infection or the composite of high-level infection and/or disease. One-year CMV infection-free survival was comparable between KTRs with or without pretransplant CMV-AbNEIs. No differences were observed by months 3 and 6. We observed no protective role for CMV-AbNEIs among CMV-seropositive KTRs undergoing T-cell-depleting induction.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiad411